Photocure ASA · OSL:PHO

Photocure ASA — Q1 2006 Earnings Presentation

16 slides from Photocure ASA's earnings presentation, Apr 20, 2006

  1. Slide 1: PhotoCure ASA First quarter 2006

    PhotoCure ASA First quarter - 2006 April 20th 2006

  2. Slide 2: Highlights First Quarter 2006

    Highlights First Quarter 2006 „ Increased sales of Metvix – Sales revenue of Metvix increased 51% to NOK 12.9 million - Metvix units up 34% in the Nordic countries - Metvix units up 73% outside the Nordic countries „ Hexvix ready for commercialisation – Licencing agreement with GE Healthcare – Intro

  3. Slide 3: Financial statements

    Financial statements

  4. Slide 4: Financial Statements - Profit & Loss (group)

    Financial Statements - Profit & Loss (group) 2006 2005 2005 01.01 - 31.03 01.01 - 31.03 01.01 - 31.12 Sales revenues 13 285 8 799 38 007 Milestone revenues 60 538 3 908 15 634 Sales and milestone revenues 73 823 12 707 53 641 Cost of products sold -3 564 -3 903 -13 430 Gross profit 70 259 8 804 40 2

  5. Slide 5: Financial Statements - Segment Information (group)

    Financial Statements - Segment Information (group) Income statement - geographical distribution (Amounts in NOK 1000) 1Q06 1Q05 Un- Un- Nordic ROW allocated Total Nordic ROW allocated Total Sales revenue 5 710 7 575 13 285 3 891 4 908 0 8 799 Milestone revenue 0 60 538 60 538 0 3 908 0 3 908 Total r

  6. Slide 6: Financial statements - Balance Sheet (group)

    Financial statements - Balance Sheet (group) 2006 2005 2005 31.03 31.03 31.12 Machinery & equipment 2 844 1 842 2 708 Financial fixed assets - - - Total fixed assets 2 844 1 842 2 708 Currrent assets Inventory 11 044 16 613 12 943 Receivables 21 981 15 023 17 725 Cash & cash equivalents 296 771 117

  7. Slide 7: Financial statements - Cash Flow Statement (group)

    Financial statements - Cash Flow Statement (group) Three months ended 2005 31.03.2006 31.03.2005 01.01 - 31.12 Income/loss(-) before tax 42 970 -13 094 -38 474 Interest paid -9 -20 -63 Other operational items -10 789 -7 449 -32 004 Net cash flow from operations 32 171 -20 563 -70 540 Cash flow from

  8. Slide 8: Metvix and Aktilite - treatment of skin cancer without scarring

    Metvix® and Aktilite™ - treatment of skin cancer without scarring

  9. Slide 9: Metvix - Nordic sales increase of 41% in Q1 2006

    Metvix - Nordic sales increase of 41% in Q1 2006 Metvix Sales in Units - Nordic 2004 - 2006 Highlights: 5000 ƒ Sales revenues for Metvix/Aktilite was 4500 NOK 5.4 million in the first quarter 4000 2006, vs NOK 3.9 million in the first 3500 3000 quarter 2005, an increase of 41%. Units 2500 2000 ƒ Sal

  10. Slide 10: Metvix - Galderma sales increase of 57% in Q1 2006

    Metvix - Galderma sales increase of 57 % in Q1 2006 Metvix Sales in Units - Galderma 2004 - 2006 Highlights: ƒ Sales revenues for Metvix/Aktilite 10000 was NOK 7.4 million in the first 8000 quarter 2006, vs NOK 4.7 million in the first quarter 2005, an 6000 increase of 57%. U nits 4000 ƒ Sales incre

  11. Slide 11: Hexvix - a breakthrough in bladder cancer

    Hexvix® – a breakthrough in bladder cancer

  12. Slide 12: Regulatory status for Hexvix

    Regulatory status for Hexvix „ National approval in most European countries secured through the MRP procedure. „ NDA submitted June 2005 „ Non-approvable letter received from the FDA in April 2006 requesting - additional analyses - more clinical documentation „ PhotoCure will, together with its US r

  13. Slide 13: Licencing agreement with GE Healthcare for Hexvix

    Licencing agreement with GE Healthcare for Hexvix „ GE Healthcare - world leader in imaging drugs „ Agreement signed January 2006 – Exclusive rights to market and distribute Hexvix outside of the Nordic region – Option to licence in the US – Total milestones of € 28 million, of which € 7 million at

  14. Slide 14: European introduction of Hexvix started

    European introduction of Hexvix started „ PhotoCure and GE Healthcare arranged a Hexvix symposium and exhibition at EAU in Paris – 10 000 participants – GE conducted an in depth survey of 400 urologists „ GE Healthcare initiated internal Hexvix training of key marketing and sales personell in Europe

  15. Slide 15: Goals and milestones

    Goals and milestones

  16. Slide 16: Strategic and operational goals

    Strategic and operational goals „ Continue investing in Metvix and Aktilite – Support Galderma in strengthening Metvix/Aktilite in dermatology – Seek Aktilite approval in the US – planning launch in 2008 „ Commercialise Hexvix – Continue Nordic launch – Support GE Healthcare in launching Hexvix – Fo

PhotoCure — Q1 2006 Earnings Presentation on 6ix